{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:37:35Z","timestamp":1778625455590,"version":"3.51.4"},"reference-count":240,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T00:00:00Z","timestamp":1695513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cardiomyopathies represent significant contributors to cardiovascular morbidity and mortality. Over the past decades, a progress has occurred in characterization of the genetic background and major pathophysiological mechanisms, which has been incorporated into a more nuanced diagnostic approach and risk stratification. Furthermore, medications targeting core disease processes and\/or their downstream adverse effects have been introduced for several cardiomyopathies. Combined with standard care and prevention of sudden cardiac death, these novel and emerging targeted therapies offer a possibility of improving the outcomes in several cardiomyopathies. Therefore, the aim of this document is to summarize practical approaches to the treatment of cardiomyopathies, which includes the evidence-based novel therapeutic concepts and established principles of care, tailored to the individual patient aetiology and clinical presentation of the cardiomyopathy. The scope of the document encompasses contemporary treatment of dilated, hypertrophic, restrictive and arrhythmogenic cardiomyopathy. It was based on an expert consensus reached at the Heart Failure Association online Workshop, held on 18 March 2021.<\/jats:p>","DOI":"10.1002\/ejhf.2979","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T06:12:03Z","timestamp":1689833523000},"page":"1899-1922","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["State-of-the-Art Document on Optimal Contemporary Management of Cardiomyopathies"],"prefix":"10.1093","volume":"25","author":[{"given":"Petar M.","family":"Seferovi\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Serbian Academy of Sciences and Arts , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marija","family":"Polovina","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Department of Cardiology, University Clinical Centre of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Pisana , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biykem","family":"Bozkurt","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medicine, Baylor College of Medicine , Houston, TX ,","place":["USA"]},{"name":"Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center , Houston, TX ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Metra","sequence":"additional","affiliation":[{"name":"Cardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, CARIM, Maastricht University Medical Centre , Maastricht ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilfried","family":"Mullens","sequence":"additional","affiliation":[{"name":"Hasselt University , Hasselt ,","place":["Belgium"]},{"name":"Ziekenhuis Oost-Limburg , Genk ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, Hannover Medical School , Hannover ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Sliwa","sequence":"additional","affiliation":[{"name":"Cape Heart Institute, Division of Cardiology, Groote Schuur Hospital, Faculty of Health Sciences, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Thoraxcenter, Erasmus Medical Center , Rotterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"University of Cyprus Medical School , Nicosia ,","place":["Cyprus"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[{"name":"Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School , Hannover ,","place":["Germany"]},{"name":"Fraunhofer Cluster of Excellence Immune-Mediated Diseases (CIMD) , Hannover ,","place":["Germany"]},{"name":"Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) , Hannover ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Medicine, University of Florence, Meyer Children's Hospital and Careggi University Hospital , Florence ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio","family":"Rapezzi","sequence":"additional","affiliation":[{"name":"Cardiology Centre, University of Ferrara , Ferrara ,","place":["Italy"]},{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ale\u0161","family":"Linhart","sequence":"additional","affiliation":[{"name":"Second Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital , Prague ,","place":["Czech Republic"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Domenico","family":"Corrado","sequence":"additional","affiliation":[{"name":"Department of Cardio-Thoraco-Vascular Sciences and Public Health, University of Padua , Padua ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carsten","family":"Tsch\u00f6pe","sequence":"additional","affiliation":[{"name":"Berlin Institute of Health (BIH) at Charit\u00e9-Universit\u00e4tsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT) , Berlin ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research , Berlin ,","place":["Germany"]},{"name":"Department of Cardiology, Charit\u00e9-Universit\u00e4tsmedizin Berlin , Berlin ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Milinkovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Department of Cardiology, University Clinical Centre of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoni","family":"Bayes Genis","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Hospital Universitari Germans Trias i Pujol, CIBERCV, Universidad Aut\u00f3noma de Barcelona , Badalona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[{"name":"National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital , Athens ,","place":["Greece"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Keren","sequence":"additional","affiliation":[{"name":"Heart Institute, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem , Jerusalem ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milika","family":"A\u0161anin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Department of Cardiology, University Clinical Centre of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Krljanac","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Department of Cardiology, University Clinical Centre of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru\u017eica","family":"Maksimovi\u0107","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Belgrade University , Belgrade ,","place":["Serbia"]},{"name":"Center for Radiology and Magnetic Resonance, University Clinical Center of Serbia , Belgrade ,","place":["Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Skouri","sequence":"additional","affiliation":[{"name":"Division of Cardiology, American University of Beirut Medical Center , Beirut ,","place":["Lebanon"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuvia","family":"Ben Gal","sequence":"additional","affiliation":[{"name":"Heart Failure Unit, Cardiology Department, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University , Tel Aviv ,","place":["Israel"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Moura","sequence":"additional","affiliation":[{"name":"Armed Forces Hospital, Porto, & Faculty of Medicine, University of Porto , Porto ,","place":["Portugal"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Volterrani","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Pisana , Rome ,","place":["Italy"]},{"name":"Department of Human Science and Promotion of Quality of Life, San Raffaele Open University of Rome , Rome ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdy","family":"Abdelhamid","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Faculty of Medicine, Kasr Al Ainy, Cairo University , Giza ,","place":["Egypt"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuri","family":"Lopatin","sequence":"additional","affiliation":[{"name":"Volgograd Medical University, Cardiology Centre , Volgograd ,","place":["Russian Federation"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidiu","family":"Chioncel","sequence":"additional","affiliation":[{"name":"Emergency Institute for Cardiovascular Diseases \u2018Prof. Dr. C.C. Iliescu\u2019 Bucharest; University for Medicine and Pharmacy \u2018Carol Davila\u2019 Bucharest , Bucharest ,","place":["Romania"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.S.","family":"Coats","sequence":"additional","affiliation":[{"name":"University of Warwick , Coventry ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,24]]},"reference":[{"key":"2026010913115501900_ejhf2979-bib-0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/ejhf.2333","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"24","author":"McDonagh","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0002","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: A position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0003","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ejhf.1914","article-title":"Contemporary survival trends and aetiological characterization in non-ischaemic dilated cardiomyopathy","volume":"22","author":"Merlo","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0004","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ejhf.2414","article-title":"Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: From molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC)","volume":"24","author":"de Boer","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0005","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases","volume":"37","author":"Pinto","year":"2016","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0006","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jacc.2011.08.078","article-title":"Risk factors for malignant ventricular arrhythmias in lamin A\/C mutation carriers: A European cohort study","volume":"59","author":"van Rijsingen","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0007","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: The heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026010913115501900_ejhf2979-bib-0008","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41569-019-0284-0","article-title":"Genetics of dilated cardiomyopathy: Practical implications for heart failure management","volume":"17","author":"Rosenbaum","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0009","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00392-016-1033-6","article-title":"Genotype-phenotype associations in dilated cardiomyopathy: Meta-analysis on more than 8000 individuals","volume":"106","author":"Kayvanpour","year":"2017","journal-title":"Clin Res Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0010","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2017.09.006","article-title":"Biological phenotypes of heart failure with preserved ejection fraction","volume":"70","author":"Lewis","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0011","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacc.2015.07.023","article-title":"Prognostic relevance of gene-environment interactions in patients with dilated cardiomyopathy: Applying the MOGE(S) classification","volume":"66","author":"Hazebroek","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0012","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005220","article-title":"Clinical phenotype and genotype associations with improvement in left ventricular function in dilated cardiomyopathy","volume":"11","author":"Verdonschot","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009352","article-title":"Dynamic ejection fraction trajectory in patients with dilated cardiomyopathy with a truncating titin variant","volume":"15","author":"Henkens","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0014","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jacc.2022.06.040","article-title":"Clinical risk score to predict pathogenic genotypes in patients with dilated cardiomyopathy","volume":"80","author":"Escobar-Lopez","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0015","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1161\/CIRCULATIONAHA.118.039410","article-title":"Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies","volume":"140","author":"Wahbi","year":"2019","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0016","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jama.2023.3371","article-title":"Diagnosis and treatment of acute myocarditis: A review","volume":"329","author":"Ammirati","year":"2023","journal-title":"JAMA"},{"key":"2026010913115501900_ejhf2979-bib-0017","doi-asserted-by":"crossref","first-page":"bcr2017223523","DOI":"10.1136\/bcr-2017-223523","article-title":"Myocarditis secondary to smallpox vaccination","volume":"2018","author":"Keinath","year":"2018","journal-title":"BMJ Case Rep"},{"key":"2026010913115501900_ejhf2979-bib-0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s40266-022-00997-0","article-title":"The incidence of myocarditis following an influenza vaccination: A population-based observational study","volume":"40","author":"Wang","year":"2023","journal-title":"Drugs Aging"},{"key":"2026010913115501900_ejhf2979-bib-0019","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/CIRCULATIONAHA.121.058457","article-title":"Genetic architecture of acute myocarditis and the overlap with inherited cardiomyopathy","volume":"146","author":"Lota","year":"2022","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/ejhf.2190","article-title":"Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy","volume":"23","author":"Seferovi\u0107","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: An expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0022","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","article-title":"Usefulness of immunosuppression for giant cell myocarditis","volume":"102","author":"Cooper","year":"2008","journal-title":"Am J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0023","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.jacc.2017.09.023","article-title":"Eosinophilic myocarditis: Characteristics, treatment, and outcomes","volume":"70","author":"Brambatti","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0024","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: A review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"2026010913115501900_ejhf2979-bib-0025","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cjco.2020.10.017","article-title":"Effect of acute immunosuppression on left ventricular recovery and mortality in fulminant viral myocarditis: A case series and review of literature","volume":"3","author":"Turgeon","year":"2021","journal-title":"CJC Open"},{"key":"2026010913115501900_ejhf2979-bib-0026","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/eurheartj\/ehaa605","article-title":"2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease","volume":"42","author":"Pelliccia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0027","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1056\/NEJM199508033330501","article-title":"A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators","volume":"333","author":"Mason","year":"1995","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0028","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1161\/01.CIR.104.1.39","article-title":"Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy","volume":"104","author":"Wojnicz","year":"2001","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0029","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: The TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0030","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1093\/eurheartj\/ehac348","article-title":"Immunosuppressive therapy in virus-negative inflammatory cardiomyopathy: 20-year follow-up of the TIMIC trial","volume":"43","author":"Chimenti","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0031","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004228","article-title":"Immunosuppressive therapy improves both short- and long-term prognosis in patients with virus-negative nonfulminant inflammatory cardiomyopathy","volume":"11","author":"Merken","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0032","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/ejhf.1560","article-title":"Immunosuppression in inflammatory cardiomyopathy and parvovirus B19 persistence","volume":"21","author":"Tsch\u00f6pe","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0033","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00392-016-0986-9","article-title":"Betaferon in chronic viral cardiomyopathy (BICC) trial: Effects of interferon-\u03b2 treatment in patients with chronic viral cardiomyopathy","volume":"105","author":"Schultheiss","year":"2016","journal-title":"Clin Res Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0034","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0735-1097(00)00568-4","article-title":"Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: Three-month results from a randomized study","volume":"35","author":"Felix","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0035","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jjcc.2016.07.014","article-title":"Therapeutic effect of immunoadsorption and subsequent immunoglobulin substitution in patients with dilated cardiomyopathy: Results from the observational prospective Bad Berka Registry","volume":"69","author":"Ohlow","year":"2017","journal-title":"J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0036","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1093\/eurheartj\/ehab458","article-title":"Peripartum cardiomyopathy: From genetics to management","volume":"42","author":"Sliwa","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0037","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0038","doi-asserted-by":"crossref","first-page":"820","DOI":"10.12659\/AJCR.909601","article-title":"Severe course of peripartum cardiomyopathy and subsequent recovery in a patient with a novel TTN gene-truncating mutation","volume":"19","author":"Kryczka","year":"2018","journal-title":"Am J Case Rep"},{"key":"2026010913115501900_ejhf2979-bib-0039","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/genes12010103","article-title":"Genetics of peripartum cardiomyopathy: Current knowledge, future directions and clinical implications","volume":"12","author":"Spracklen","year":"2021","journal-title":"Genes (Basel)"},{"key":"2026010913115501900_ejhf2979-bib-0040","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1093\/eurheartj\/ehaa455","article-title":"Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: An ESC EORP registry","volume":"41","author":"Sliwa","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0041","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/ejhf.586","article-title":"Current management of patients with severe acute peripartum cardiomyopathy: Practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"18","author":"Bauersachs","year":"2016","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0042","first-page":"349","article-title":"Low STAT3 expression sensitizes to toxic effects of \u03b2-adrenergic receptor stimulation in peripartum cardiomyopathy","volume":"38","author":"Stapel","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0043","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00392-010-0279-7","article-title":"Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial","volume":"100","author":"Biteker","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0044","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4103\/1687-7934.133308","article-title":"Comparison between milrinone and levosimendan infusion in patients with peripartum cardiomyopathy","volume":"7","author":"Abdel Hamid","year":"2014","journal-title":"Ain Shams J Anaesthesiol"},{"key":"2026010913115501900_ejhf2979-bib-0045","first-page":"173","article-title":"Cardiogenic shock complicating peripartum cardiomyopathy: Importance of early left ventricular unloading and bromocriptine therapy","volume":"9","author":"Sieweke","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"2026010913115501900_ejhf2979-bib-0046","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/aor.14406","article-title":"Clinical characteristics and long-term outcomes in patients with peripartum cardiomyopathy (PPCM) receiving left ventricular assist devices (LVAD)","volume":"47","author":"Berliner","year":"2023","journal-title":"Artif Organs"},{"key":"2026010913115501900_ejhf2979-bib-0047","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/cvr\/cvz252","article-title":"Peripartum cardiomyopathy: Basic mechanisms and hope for new therapies","volume":"116","author":"Ricke-Hoch","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026010913115501900_ejhf2979-bib-0048","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehx355","article-title":"Bromocriptine for the treatment of peripartum cardiomyopathy: A multicentre randomized study","volume":"38","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0049","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy","volume":"39","author":"Regitz-Zagrosek","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0050","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s00392-018-1355-7","article-title":"Bromocriptine treatment in patients with peripartum cardiomyopathy and right ventricular dysfunction","volume":"108","author":"Haghikia","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0051","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacc.2014.07.961","article-title":"Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy","volume":"64","author":"Elkayam","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0052","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0053","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"L\u00f3pez-Send\u00f3n","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0054","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/ejhf.1172","article-title":"Anthracycline-induced cardiomyopathy: Secrets and lies","volume":"20","author":"Farmakis","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-induced cardiomyopathy: Clinical relevance and response to pharmacologic therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0056","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0057","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"\u010celutkien\u0117","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0058","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0059","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026010913115501900_ejhf2979-bib-0060","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor\u2013associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0061","doi-asserted-by":"crossref","first-page":"683","DOI":"10.7326\/L17-0396","article-title":"Survival after fulminant myocarditis induced by immune-checkpoint inhibitors","volume":"167","author":"Arangalage","year":"2017","journal-title":"Ann Intern Med"},{"key":"2026010913115501900_ejhf2979-bib-0062","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0063","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0064","doi-asserted-by":"crossref","first-page":"e1925","DOI":"10.1097\/MJT.0000000000000430","article-title":"Left ventricular dysfunction after treatment with ipilimumab for metastatic melanoma","volume":"23","author":"Roth","year":"2016","journal-title":"Am J Ther"},{"key":"2026010913115501900_ejhf2979-bib-0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ejca.2018.02.005","article-title":"Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial","volume":"94","author":"Cardinale","year":"2018","journal-title":"Eur J Cancer"},{"key":"2026010913115501900_ejhf2979-bib-0066","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0067","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0068","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2026010913115501900_ejhf2979-bib-0069","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ehf2.12627","article-title":"Effectiveness of sacubitril-valsartan in cancer patients with heart failure","volume":"7","author":"Mart\u00edn-Garcia","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0070","first-page":"35","article-title":"Sacubitril\/valsartan is well tolerated in patients with longstanding heart failure and history of cancer and improves ventricular function: Real-world data","volume":"7","author":"Frey","year":"2021","journal-title":"Cardiooncology"},{"key":"2026010913115501900_ejhf2979-bib-0071","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00380-008-1144-8","article-title":"Cardiotoxicity after low-dose chloroquine antimalarial therapy","volume":"24","author":"Fragasso","year":"2009","journal-title":"Heart Vessels"},{"key":"2026010913115501900_ejhf2979-bib-0072","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000094079","article-title":"Cardiomyopathy related to antimalarial therapy with illustrative case report","volume":"107","author":"Costedoat-Chalumeau","year":"2006","journal-title":"Cardiology"},{"key":"2026010913115501900_ejhf2979-bib-0073","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","article-title":"Drugs that may cause or exacerbate heart failure","volume":"134","author":"Page","year":"2016","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0074","first-page":"238","article-title":"Antipsychotic cardiomyopathy: To the problem of clinical diagnosis","volume":"4","author":"Volkov","year":"2018","journal-title":"MOJ Toxicol"},{"key":"2026010913115501900_ejhf2979-bib-0075","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4088\/JCP.09m05024yel","article-title":"Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls","volume":"71","author":"Ronaldson","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"2026010913115501900_ejhf2979-bib-0076","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1177\/0269881106059696","article-title":"Cardiomyopathy after long-term treatment with lithium \u2013 more than a coincidence?","volume":"20","author":"Aichhorn","year":"2006","journal-title":"J Psychopharmacol"},{"key":"2026010913115501900_ejhf2979-bib-0077","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1016\/j.jacc.2019.02.045","article-title":"Arrhythmia-induced cardiomyopathy: JACC state-of-the-art review","volume":"73","author":"Huizar","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0078","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.hrthm.2010.03.036","article-title":"Relationship between burden of premature ventricular complexes and left ventricular function","volume":"7","author":"Baman","year":"2010","journal-title":"Heart Rhythm"},{"key":"2026010913115501900_ejhf2979-bib-0079","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/eurheartj\/ehac088","article-title":"Electrical management of heart failure: From pathophysiology to treatment","volume":"43","author":"Prinzen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0080","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/hrt.2008.158931","article-title":"A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure: (CAFE-II Study)","volume":"95","author":"Shelton","year":"2009","journal-title":"Heart"},{"key":"2026010913115501900_ejhf2979-bib-0081","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.115.019406","article-title":"Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: Results from the AATAC multicenter randomized trial","volume":"133","author":"Di Biase","year":"2016","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0082","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0083","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.jacc.2004.12.073","article-title":"Radiofrequency catheter ablation of premature ventricular complexes from right ventricular outflow tract improves left ventricular dilation and clinical status in patients without structural heart disease","volume":"45","author":"Takemoto","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0084","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1536\/ihj.49.39","article-title":"Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy","volume":"49","author":"Watanabe","year":"2008","journal-title":"Int Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0085","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.CIR.0000135472.28234.CC","article-title":"Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia","volume":"110","author":"Nerheim","year":"2004","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0086","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/S0140-6736(18)30134-X","article-title":"Risk thresholds for alcohol consumption: Combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies","volume":"391","author":"Wood","year":"2018","journal-title":"Lancet"},{"key":"2026010913115501900_ejhf2979-bib-0087","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.009459","article-title":"Alcohol intake in patients with cardiomyopathy and heart failure: Consensus and controversy","volume":"15","author":"Andersson","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0088","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2014.07.014","article-title":"Natural history and prognostic factors in alcoholic cardiomyopathy","volume":"3","author":"Guzzo-Merello","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0089","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.eurheartj.a014842","article-title":"Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy","volume":"17","author":"Prazak","year":"1996","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0090","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: A scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0091","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12012-015-9350-y","article-title":"Methamphetamine-associated congestive heart failure: Increasing prevalence and relationship of clinical outcomes to continued use or abstinence","volume":"16","author":"Sliman","year":"2016","journal-title":"Cardiovasc Toxicol"},{"key":"2026010913115501900_ejhf2979-bib-0092","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/CIRCULATIONAHA.113.004574","article-title":"Heart failure in patients with human immunodeficiency virus infection","volume":"129","author":"Remick","year":"2014","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0093","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/eurheartj\/ehs471","article-title":"Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: A meta-analysis in the highly active antiretroviral therapy era","volume":"34","author":"Cerrato","year":"2013","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0094","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/01.qai.0000179459.31562.16","article-title":"Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras","volume":"41","author":"Crum","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2026010913115501900_ejhf2979-bib-0095","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1053\/pcad.2000.9031","article-title":"Cardiomyopathy in AIDS: A pathophysiological perspective","volume":"43","author":"Lewis","year":"2000","journal-title":"Prog Cardiovasc Dis"},{"key":"2026010913115501900_ejhf2979-bib-0096","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: A multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"2026010913115501900_ejhf2979-bib-0097","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.healun.2011.07.022","article-title":"Heart transplantation in HIV-infected patients: More cases in Europe","volume":"30","author":"Castel","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"2026010913115501900_ejhf2979-bib-0098","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejhf.1236","article-title":"Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology","volume":"20","author":"Crespo-Leiro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0099","doi-asserted-by":"crossref","first-page":"S121 (abstr)","DOI":"10.1016\/j.healun.2022.01.283","article-title":"Clinical outcomes and survival of HIV positive and negative patients on LVAD support","volume":"41","author":"Birk","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"2026010913115501900_ejhf2979-bib-0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00059-021-05020-7","article-title":"Neglected cardiovascular diseases and their significance in the Global North","volume":"46","author":"Viljoen","year":"2021","journal-title":"Herz"},{"key":"2026010913115501900_ejhf2979-bib-0101","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.jacc.2013.05.046","article-title":"Chagas disease: An overview of clinical and epidemiological aspects","volume":"62","author":"Nunes","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0102","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.106.624296","article-title":"Pathogenesis of chronic Chagas heart disease","volume":"115","author":"Marin-Neto","year":"2007","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0103","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1161\/CIR.0000000000000599","article-title":"Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association","volume":"138","author":"Nunes","year":"2018","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0104","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas' cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0105","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12996","article-title":"Reactivation of Chagas disease among heart transplant recipients in the United States, 2012-2016","volume":"20","author":"Gray","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2026010913115501900_ejhf2979-bib-0106","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.765879","article-title":"Immunomodulation for the treatment of chronic Chagas disease cardiomyopathy: A new approach to an old enemy","volume":"11","author":"Santos","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"issue":"2","key":"2026010913115501900_ejhf2979-bib-0107","first-page":"213","article-title":"Lyme borreliosis infection as a cause of dilated cardiomyopathy","volume":"107","author":"Bart\u016fnek","year":"2006","journal-title":"Prague Med Rep"},{"key":"2026010913115501900_ejhf2979-bib-0108","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s00059-015-4308-1","article-title":"Recent-onset dilated cardiomyopathy associated with Borrelia burgdorferi infection","volume":"40","author":"Kuchynka","year":"2015","journal-title":"Herz"},{"key":"2026010913115501900_ejhf2979-bib-0109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.hlc.2006.07.013","article-title":"Nutritional deficiency of selenium secondary to weight loss (bariatric) surgery associated with life-threatening cardiomyopathy","volume":"16","author":"Boldery","year":"2007","journal-title":"Heart Lung Circ"},{"key":"2026010913115501900_ejhf2979-bib-0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/archdischild-2019-317794","article-title":"Vitamin D deficiency cardiomyopathy in Scotland: A retrospective review of the last decade","volume":"105","author":"Hunter","year":"2020","journal-title":"Arch Dis Child"},{"key":"2026010913115501900_ejhf2979-bib-0111","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1023\/A:1006826620218","article-title":"Carnitine deficiency-induced cardiomyopathy","volume":"180","author":"Paulson","year":"1998","journal-title":"Mol Cell Biochem"},{"key":"2026010913115501900_ejhf2979-bib-0112","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/nyas.14536","article-title":"Thiamine deficiency disorders: A clinical perspective","volume":"1498","author":"Smith","year":"2021","journal-title":"Ann N Y Acad Sci"},{"key":"2026010913115501900_ejhf2979-bib-0113","doi-asserted-by":"crossref","first-page":"700","DOI":"10.3390\/nu14030700","article-title":"An emerging role of defective copper metabolism in heart disease","volume":"14","author":"Liu","year":"2022","journal-title":"Nutrients"},{"key":"2026010913115501900_ejhf2979-bib-0114","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International expert consensus document on Takotsubo syndrome (Part I): Clinical characteristics, diagnostic criteria, and pathophysiology","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0115","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4250\/jcvi.2019.0083","article-title":"Time course of functional recovery in Takotsubo (stress) cardiomyopathy: A serial speckle tracking echocardiography and electrocardiography study","volume":"28","author":"Lee","year":"2020","journal-title":"J Cardiovasc Imaging"},{"key":"2026010913115501900_ejhf2979-bib-0116","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa1406761","article-title":"Clinical features and outcomes of Takotsubo (stress) cardiomyopathy","volume":"373","author":"Templin","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0117","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehy077","article-title":"International expert consensus document on Takotsubo syndrome (Part II): Diagnostic workup, outcome, and management","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0118","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's disease with the pharmacologic chaperone migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0119","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1002\/ehf2.13486","article-title":"Levosimendan improves the acute course of takotsubo syndrome: A pooled analysis","volume":"8","author":"Jaguszewski","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0120","first-page":"84","article-title":"Cardiogenic shock in Takotsubo cardiomyopathy: A focus on management","volume":"31","author":"Doucet","year":"2015","journal-title":"Can J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0121","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.carrev.2021.11.018","article-title":"Impella mechanical circulatory support for Takotsubo syndrome with shock: A retrospective multicenter analysis","volume":"40","author":"Napp","year":"2022","journal-title":"Cardiovasc Revasc Med"},{"key":"2026010913115501900_ejhf2979-bib-0122","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCULATIONAHA.118.036164","article-title":"Outcomes associated with cardiogenic shock in Takotsubo syndrome","volume":"139","author":"Vece","year":"2019","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0123","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1136\/heartjnl-2020-318028","article-title":"Survival and risk of recurrence of takotsubo syndrome","volume":"107","author":"Lau","year":"2021","journal-title":"Heart"},{"key":"2026010913115501900_ejhf2979-bib-0124","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0125","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0126","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1161\/CIRCRESAHA.121.318346","article-title":"Molecular genetic basis of hypertrophic cardiomyopathy","volume":"128","author":"Marian","year":"2021","journal-title":"Circ Res"},{"key":"2026010913115501900_ejhf2979-bib-0127","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910401","article-title":"Genetic testing in patients with hypertrophic cardiomyopathy","volume":"22","author":"Bonaventura","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026010913115501900_ejhf2979-bib-0128","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/cge.13157","article-title":"Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy","volume":"93","author":"Mathew","year":"2018","journal-title":"Clin Genet"},{"key":"2026010913115501900_ejhf2979-bib-0129","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.amjcard.2016.06.038","article-title":"Value of genetic testing for the prediction of long-term outcome in patients with hypertrophic cardiomyopathy","volume":"118","author":"van Velzen","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0130","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0131","doi-asserted-by":"crossref","first-page":"11957","DOI":"10.1038\/s41598-017-12289-4","article-title":"Survival and prognostic factors in hypertrophic cardiomyopathy: A meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"2026010913115501900_ejhf2979-bib-0132","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1161\/CIRCULATIONAHA.119.044366","article-title":"Hypertrophic cardiomyopathy with left ventricular systolic dysfunction: Insights from the SHaRe registry","volume":"141","author":"Marstrand","year":"2020","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0133","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/j.jacc.2020.08.045","article-title":"2020 AHA\/ACC Guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"76","author":"Ommen","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0134","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0135","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/eurheartj\/ehs150","article-title":"Pharmacological treatment options for hypertrophic cardiomyopathy: High time for evidence","volume":"33","author":"Spoladore","year":"2012","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0136","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1038\/s41591-021-01505-4","article-title":"Valsartan in early-stage hypertrophic cardiomyopathy: A randomized phase 2 trial","volume":"27","author":"Ho","year":"2021","journal-title":"Nat Med"},{"key":"2026010913115501900_ejhf2979-bib-0137","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.cardfail.2017.09.011","article-title":"Outcomes of restrictive and hypertrophic cardiomyopathies after LVAD: An INTERMACS analysis","volume":"23","author":"Patel","year":"2017","journal-title":"J Card Fail"},{"key":"2026010913115501900_ejhf2979-bib-0138","doi-asserted-by":"crossref","first-page":"318","DOI":"10.21037\/acs.2017.04.03","article-title":"Surgical treatment for hypertrophic cardiomyopathy: A historical perspective","volume":"6","author":"Hang","year":"2017","journal-title":"Ann Cardiothorac Surg"},{"key":"2026010913115501900_ejhf2979-bib-0139","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijcard.2022.09.036","article-title":"Does a standard myectomy exist for obstructive hypertrophic cardiomyopathy? From the Morrow variations to precision surgery","volume":"371","author":"Stef\u00e0no","year":"2023","journal-title":"Int J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0140","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jchf.2015.06.011","article-title":"A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy","volume":"3","author":"Liebregts","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0141","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/CIRCULATIONAHA.119.042339","article-title":"Myosin sequestration regulates sarcomere function, cardiomyocyte energetics, and metabolism, informing the pathogenesis of hypertrophic cardiomyopathy","volume":"141","author":"Toepfer","year":"2020","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0142","doi-asserted-by":"crossref","first-page":"741","DOI":"10.7326\/M18-3016","article-title":"Mavacamten treatment for obstructive hypertrophic cardiomyopathy: A clinical trial","volume":"170","author":"Heitner","year":"2019","journal-title":"Ann Intern Med"},{"key":"2026010913115501900_ejhf2979-bib-0143","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"},{"key":"2026010913115501900_ejhf2979-bib-0144","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","article-title":"Effect of mavacamten on echocardiographic features in symptomatic patients with obstructive hypertrophic cardiomyopathy","volume":"78","author":"Hegde","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0145","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(21)01891-X","article-title":"Long-term safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy: Interim results of the MAVA-Long Term Extension (LTE) study","volume":"77","author":"Rader","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0146","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","article-title":"Myosin inhibition in patients with obstructive hypertrophic cardiomyopathy referred for septal reduction therapy","volume":"80","author":"Desai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.04.020","article-title":"Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond","volume":"102","author":"Morelli","year":"2022","journal-title":"Eur J Intern Med"},{"key":"2026010913115501900_ejhf2979-bib-0148","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0149","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/eurjpc\/zwab181","article-title":"External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathy","volume":"29","author":"Norrish","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of \u03b2-blockers, amiodarone plus \u03b2-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: The OPTIC study: A randomized trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"2026010913115501900_ejhf2979-bib-0151","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jacep.2017.12.020","article-title":"Radiofrequency catheter ablation of ventricular tachycardia in patients with hypertrophic cardiomyopathy and apical aneurysm","volume":"4","author":"Igarashi","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"2026010913115501900_ejhf2979-bib-0152","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.hrthm.2010.05.022","article-title":"Radiofrequency catheter ablation of ventricular arrhythmias in patients with hypertrophic cardiomyopathy: Safety and feasibility","volume":"7","author":"Santangeli","year":"2010","journal-title":"Heart Rhythm"},{"key":"2026010913115501900_ejhf2979-bib-0153","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","article-title":"Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review","volume":"100","author":"Guttmann","year":"2014","journal-title":"Heart"},{"key":"2026010913115501900_ejhf2979-bib-0154","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/ejhf.316","article-title":"Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk-CVA)","volume":"17","author":"Guttmann","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0155","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00380-020-01728-4","article-title":"Prognostic impact of newly detected atrial fibrillation in patients with hypertrophic cardiomyopathy following cardiac implantable electronic device implantation","volume":"36","author":"Hayashi","year":"2021","journal-title":"Heart Vessels"},{"key":"2026010913115501900_ejhf2979-bib-0156","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/eurheartj\/ehx731","article-title":"Subclinical device-detected atrial fibrillation and stroke risk: A systematic review and meta-analysis","volume":"39","author":"Mahajan","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0157","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/heartjnl-2016-309406","article-title":"Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: A systematic review and meta-analysis","volume":"102","author":"Providencia","year":"2016","journal-title":"Heart"},{"key":"2026010913115501900_ejhf2979-bib-0158","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/europace\/euab022","article-title":"Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: A European observational multicentre study","volume":"23","author":"Creta","year":"2021","journal-title":"Europace"},{"key":"2026010913115501900_ejhf2979-bib-0159","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1093\/eurheartj\/ehac543","article-title":"Restrictive cardiomyopathy: Definition and diagnosis","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0160","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/j.jacep.2019.10.013","article-title":"No association between CHADS-VASc score and left atrial appendage thrombus in patients with transthyretin amyloidosis","volume":"5","author":"Donnellan","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"2026010913115501900_ejhf2979-bib-0161","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/13506129.2020.1798922","article-title":"Arterial thrombo-embolic events in cardiac amyloidosis: A look beyond atrial fibrillation","volume":"28","author":"Cappelli","year":"2021","journal-title":"Amyloid"},{"key":"2026010913115501900_ejhf2979-bib-0162","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jacc.2018.01.016","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: Part 1 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0163","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0735-1097(98)00026-6","article-title":"Restrictive cardiomyopathy, atrioventricular block and mild to subclinical myopathy in patients with desmin-immunoreactive material deposits","volume":"31","author":"Arbustini","year":"1998","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0164","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0735-1097(03)00759-9","article-title":"Asymptomatic cardiac disease following mediastinal irradiation","volume":"42","author":"Heidenreich","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0165","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/096721099600400221","article-title":"Changes in the proportion of types I and III collagen in the left ventricular wall of patients with post-irradiative pericarditis","volume":"4","author":"Chello","year":"1996","journal-title":"Cardiovasc Surg"},{"key":"2026010913115501900_ejhf2979-bib-0166","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0167","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0168","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0169","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0170","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0171","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0172","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.122.009637","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0173","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00392-020-01799-3","article-title":"Diagnosis and treatment of cardiac amyloidosis: Position statement of the German Cardiac Society (DGK)","volume":"110","author":"Yilmaz","year":"2021","journal-title":"Clin Res Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0174","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913115501900_ejhf2979-bib-0175","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0176","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka","year":"2020","journal-title":"Circ J"},{"key":"2026010913115501900_ejhf2979-bib-0177","first-page":"322","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0178","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1177\/2047487320920756","article-title":"Management of complications of cardiac amyloidosis: 10 questions and answers","volume":"28","author":"Aimo","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0179","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","article-title":"Detection of myocardial damage in patients with sarcoidosis","volume":"120","author":"Patel","year":"2009","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0180","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"2026010913115501900_ejhf2979-bib-0181","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1016\/j.jacc.2020.08.042","article-title":"Challenges in cardiac and pulmonary sarcoidosis: JACC state-of-the-art review","volume":"76","author":"Trivieri","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0182","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"key":"2026010913115501900_ejhf2979-bib-0183","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/S0002-9149(01)01978-6","article-title":"Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone","volume":"88","author":"Yazaki","year":"2001","journal-title":"Am J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0184","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijcard.2016.10.101","article-title":"Impact of early initiation of corticosteroid therapy on cardiac function and rhythm in patients with cardiac sarcoidosis","volume":"227","author":"Padala","year":"2017","journal-title":"Int J Cardiol"},{"issue":"2","key":"2026010913115501900_ejhf2979-bib-0185","first-page":"133","article-title":"Efficacy of corticosteroids in sarcoidosis presenting with atrioventricular block","volume":"20","author":"Kato","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2026010913115501900_ejhf2979-bib-0186","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ahj.2019.10.003","article-title":"Cardiac sarcoidosis multi-center randomized controlled trial (CHASM CS-RCT)","volume":"220","author":"Birnie","year":"2020","journal-title":"Am Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0187","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.011522","article-title":"Cardiac sarcoidosis: Epidemiology, characteristics, and outcome over 25\u2009years in a nationwide study","volume":"131","author":"Kandolin","year":"2015","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0188","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1161\/CIRCULATIONAHA.121.058120","article-title":"Incidence of sudden cardiac death and life-threatening arrhythmias in clinically manifest cardiac sarcoidosis with and without current indications for an implantable cardioverter defibrillator","volume":"146","author":"Nordenswan","year":"2022","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0189","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.hfc.2017.12.003","article-title":"Genetic infiltrative cardiomyopathies","volume":"14","author":"Sweet","year":"2018","journal-title":"Heart Fail Clin"},{"key":"2026010913115501900_ejhf2979-bib-0190","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"2026010913115501900_ejhf2979-bib-0191","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J Med Genet"},{"key":"2026010913115501900_ejhf2979-bib-0192","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1093\/hmg\/ddy248","article-title":"Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types","volume":"27","author":"Welford","year":"2018","journal-title":"Hum Mol Genet"},{"key":"2026010913115501900_ejhf2979-bib-0193","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13023-017-0565-9","article-title":"Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: Safety, tolerability, and pharmacokinetics in healthy subjects","volume":"12","author":"Gu\u00e9rard","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"2026010913115501900_ejhf2979-bib-0194","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: A systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"key":"2026010913115501900_ejhf2979-bib-0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1002\/jimd.12027","article-title":"The effectiveness of enzyme replacement therapy for juvenile-onset Pompe disease: A systematic review","volume":"42","author":"Joanne","year":"2019","journal-title":"J Inherit Metab Dis"},{"key":"2026010913115501900_ejhf2979-bib-0196","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: An international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"key":"2026010913115501900_ejhf2979-bib-0197","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.acc.2016.03.002","article-title":"Transferrin saturation: A body iron biomarker","volume":"75","author":"Elsayed","year":"2016","journal-title":"Adv Clin Chem"},{"key":"2026010913115501900_ejhf2979-bib-0198","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10741-017-9616-5","article-title":"T2 mapping and T2* imaging in heart failure","volume":"22","author":"Lota","year":"2017","journal-title":"Heart Fail Rev"},{"key":"2026010913115501900_ejhf2979-bib-0199","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/vox.12896","article-title":"Diagnosis and management of hereditary haemochromatosis","volume":"115","author":"Murphree","year":"2020","journal-title":"Vox Sang"},{"key":"2026010913115501900_ejhf2979-bib-0200","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/eurheartj\/ehaa084","article-title":"Heart failure can affect everyone: The ESC Geoffrey Rose lecture","volume":"41","author":"Sliwa","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0201","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2018.01.017","article-title":"Spectrum of restrictive and infiltrative cardiomyopathies: Part 2 of a 2-part series","volume":"71","author":"Pereira","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0202","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/1744666X.2018.1425142","article-title":"Imatinib for the treatment of hypereosinophilic syndromes","volume":"14","author":"Helbig","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2026010913115501900_ejhf2979-bib-0203","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminhematol.2012.01.001","article-title":"Treatment of hypereosinophilic syndromes \u2013 the first 100\u2009years","volume":"49","author":"Butterfield","year":"2012","journal-title":"Semin Hematol"},{"key":"2026010913115501900_ejhf2979-bib-0204","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1056\/NEJMra1509267","article-title":"Arrhythmogenic right ventricular cardiomyopathy","volume":"376","author":"Corrado","year":"2017","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0205","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1161\/CIRCRESAHA.117.309345","article-title":"Arrhythmogenic cardiomyopathy","volume":"121","author":"Corrado","year":"2017","journal-title":"Circ Res"},{"key":"2026010913115501900_ejhf2979-bib-0206","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/eurheartj\/ehz669","article-title":"Arrhythmogenic right ventricular cardiomyopathy: Evaluation of the current diagnostic criteria and differential diagnosis","volume":"41","author":"Corrado","year":"2020","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0207","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2020.06.005","article-title":"Diagnosis of arrhythmogenic cardiomyopathy: The Padua criteria","volume":"319","author":"Corrado","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0208","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15420\/AER.2016.4.3","article-title":"Arrhythmogenic cardiomyopathy: Electrical and structural phenotypes","volume":"5","author":"Akdis","year":"2016","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"2026010913115501900_ejhf2979-bib-0209","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003273","article-title":"International evidence based reappraisal of genes associated with arrhythmogenic right ventricular cardiomyopathy using the Clinical Genome Resource framework","volume":"14","author":"James","year":"2021","journal-title":"Circ Genom Precis Med"},{"key":"2026010913115501900_ejhf2979-bib-0210","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.hrthm.2017.03.034","article-title":"Distinct fibrosis pattern in desmosomal and phospholamban mutation carriers in hereditary cardiomyopathies","volume":"14","author":"Sepehrkhouy","year":"2017","journal-title":"Heart Rhythm"},{"key":"2026010913115501900_ejhf2979-bib-0211","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1161\/CIRCULATIONAHA.110.976936","article-title":"Familial evaluation in arrhythmogenic right ventricular cardiomyopathy","volume":"123","author":"Quarta","year":"2011","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0212","first-page":"3227","article-title":"Treatment of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: An international task force consensus statement","volume":"36","author":"Corrado","year":"2015","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0213","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1161\/CIRCULATIONAHA.117.030792","article-title":"Risk stratification in arrhythmogenic right ventricular cardiomyopathy","volume":"136","author":"Calkins","year":"2017","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0214","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/heartjnl-2020-316944","article-title":"Arrhythmogenic left ventricular cardiomyopathy","volume":"108","author":"Corrado","year":"2022","journal-title":"Heart"},{"key":"2026010913115501900_ejhf2979-bib-0215","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1093\/eurheartj\/ehab294","article-title":"Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers \u2013 reaching the frontiers of individual risk prediction","volume":"42","author":"Verstraelen","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0216","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehab355","article-title":"Arrhythmic risk stratification in arrhythmogenic cardiomyopathy: New predictors for left-sided variants?","volume":"42","author":"Corrado","year":"2021","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0217","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1161\/01.CIR.0000103130.33451.D2","article-title":"Implantable cardioverter-defibrillator therapy for prevention of sudden death in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"108","author":"Corrado","year":"2003","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0218","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1161\/CIRCULATIONAHA.109.913871","article-title":"Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy\/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia","volume":"122","author":"Corrado","year":"2010","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0219","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jacc.2011.06.043","article-title":"Incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia\/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention","volume":"58","author":"Bhonsale","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0220","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.jacc.2016.09.951","article-title":"Arrhythmogenic right ventricular cardiomyopathy: Clinical course and predictors of arrhythmic risk","volume":"68","author":"Mazzanti","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0221","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/CIRCIMAGING.113.000210","article-title":"Different prognostic value of functional right ventricular parameters in arrhythmogenic right ventricular cardiomyopathy\/dysplasia","volume":"7","author":"Saguner","year":"2014","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026010913115501900_ejhf2979-bib-0222","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/europace\/euac014","article-title":"Incidence and predictors of sudden cardiac death in arrhythmogenic right ventricular cardiomyopathy: A pooled analysis","volume":"24","author":"Agbaedeng","year":"2022","journal-title":"Europace"},{"key":"2026010913115501900_ejhf2979-bib-0223","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008509","article-title":"Sudden cardiac death prediction in arrhythmogenic right ventricular cardiomyopathy: A multinational collaboration","volume":"14","author":"Cadrin-Tourigny","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"2026010913115501900_ejhf2979-bib-0224","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehz103","article-title":"A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy","volume":"40","author":"Cadrin-Tourigny","year":"2019","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0225","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1093\/eurheartj\/ehac298","article-title":"Implantable defibrillators in primary prevention of genetic arrhythmias. A shocking choice?","volume":"43","author":"Corrado","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0226","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1093\/eurheartj\/ehac289","article-title":"Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: External validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator","volume":"43","author":"Jord\u00e0","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0227","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1093\/eurheartj\/ehac235","article-title":"Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator","volume":"43","author":"Protonotarios","year":"2022","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0228","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.hrthm.2018.10.016","article-title":"Ablation compared with drug therapy for recurrent ventricular tachycardia in arrhythmogenic right ventricular cardiomyopathy: Results from a multicenter study","volume":"16","author":"Mahida","year":"2019","journal-title":"Heart Rhythm"},{"key":"2026010913115501900_ejhf2979-bib-0229","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(23)01053-7","article-title":"Aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy (REDWOOD-HCM Cohort 4)","volume":"81","author":"Masri","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0230","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMoa1504942","article-title":"Therapeutic clearance of amyloid by antibodies to serum amyloid P component","volume":"373","author":"Richards","year":"2015","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0231","doi-asserted-by":"crossref","first-page":"E6741","DOI":"10.1073\/pnas.1805131115","article-title":"Amyloid seeding of transthyretin by ex vivo cardiac fibrils and its inhibition","volume":"115","author":"Saelices","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026010913115501900_ejhf2979-bib-0232","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"2026010913115501900_ejhf2979-bib-0233","doi-asserted-by":"crossref","DOI":"10.1161\/circ.146.suppl_1.11117","article-title":"Phase 1 Danon disease results: The first single dose intravenous (IV) gene therapy (RP-A501) with recombinant adeno-associated virus (AAV9:LAMP2B) for a monogenic cardiomyopathy","volume":"146","author":"Rossano","year":"2022","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0234","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/CIRCULATIONAHA.119.040366","article-title":"Severe cardiac dysfunction and death caused by arrhythmogenic right ventricular cardiomyopathy type 5 are improved by inhibition of glycogen synthase kinase-3\u03b2","volume":"140","author":"Padr\u00f3n-Barthe","year":"2019","journal-title":"Circulation"},{"key":"2026010913115501900_ejhf2979-bib-0235","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1038\/ncomms7955","article-title":"Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy","volume":"6","author":"Karakikes","year":"2015","journal-title":"Nat Commun"},{"key":"2026010913115501900_ejhf2979-bib-0236","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.3390\/jcm9092770","article-title":"Modifications of titin contribute to the progression of cardiomyopathy and represent a therapeutic target for treatment of heart failure","volume":"9","author":"Tharp","year":"2020","journal-title":"J Clin Med"},{"key":"2026010913115501900_ejhf2979-bib-0237","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jacc.2009.05.038","article-title":"Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy","volume":"54","author":"Brauch","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026010913115501900_ejhf2979-bib-0238","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/eurheartj\/ehx808","article-title":"Titin cardiomyopathy leads to altered mitochondrial energetics, increased fibrosis and long-term life-threatening arrhythmias","volume":"39","author":"Verdonschot","year":"2018","journal-title":"Eur Heart J"},{"key":"2026010913115501900_ejhf2979-bib-0239","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.3389\/fphys.2018.01356","article-title":"Role of lamin A\/C gene mutations in the signaling defects leading to cardiomyopathies","volume":"9","author":"Gerbino","year":"2018","journal-title":"Front Physiol"},{"key":"2026010913115501900_ejhf2979-bib-0240","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012514","article-title":"Role of targeted therapy in dilated cardiomyopathy: The challenging road toward a personalized approach","volume":"8","author":"Verdonschot","year":"2019","journal-title":"J Am Heart Assoc"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/11\/1899\/65556301\/eurjhf_25_11_1899.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/11\/1899\/65556301\/eurjhf_25_11_1899.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:15:20Z","timestamp":1767982520000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/11\/1899\/8342924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,24]]},"references-count":240,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,9,24]]},"published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2979","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,9,24]]},"assertion":[{"value":"2023-03-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}